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Abstract
Purpose: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been
shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing
properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant rhabdoid tumor (MRT) mouse model.
Methods and material: Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor
growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and gH2AX expression as well as dynamic
18F-
Fluorodeoxyglucose Positron Emission Tomography (
18F-FDG -PET) after treatment with either SAHA alone, single-
dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls.
Results: SAHA only had no significant effect on tumor growth. Combination of SAHA for 8 days with single-dose
XRT resulted in a higher number of complete remissions, but failed to prove a significant growth delay compared
to XRT only. In contrast fractionated XRT plus SAHA for 3 weeks did induce significant tumor growth delay in MRT-
xenografts.
The histological examination showed a significant effect of XRT in tumor necrosis, expression of Ki-67, gH2AX and
apoptosis. SAHA only had no significant effect in the histological examination. Comparison of xenografts treated
with XRT and XRT plus SAHA revealed a significantly increased gH2AX expression and apoptosis induction in the
mice tumors after combination treatment with single-dose as well as fractionated XRT. The combination of SAHA
with XRT showed a tendency to increased necrosis and decrease of proliferation compared to XRT only, which,
however, was not significant. The
18F-FDG-PET results showed no significant differences in the standard uptake
value or glucose transport kinetics after either treatment.
Conclusion: SAHA did not have a significant effect alone, but proved to enhance the effect of XRT in our MRT in
vivo model.
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The aim of the present study was to evaluate the in vivo
efficacy of the HDACi SAHA in combination with XRT
in MRT xenotransplants.
MRT and their central nervous system counterpart aty-
pical teratoid/rhabdoid tumors are rare and highly malig-
nant neoplasms that primarily occur in young children.
Emerging evidence suggests an important role for radio-
therapy to achieve long-term survival. Nevertheless even
after toxic multimodal treatment including radiotherapy
outcome is generally poor and new therapy options are
urgently needed [1,2]. Therefore interest in adjuvant
agents that selectively augment the response of MRT to
radiation and thus increase the therapeutic ratio is high.
Histone deacetylase inhibitiors (HDACi) are under inves-
tigation in anti-cancer treatment. They work by epige-
netic regulation of gene expression, induce cell growth
arrest, apoptosis as well as terminal differentiation. Clini-
cal trials so far indicate moderate toxicity and favorable
safety profiles. Even though in single-agent treatments
only moderate improvements in outcome were observed
[3], the combination of HDACi with other therapy mod-
alities like radiotherapy has been reported to improve the
therapeutic effect in many tumor entities in cell lines and
xenograft tumor models [4-7]. We recently reported that
the HDACi suberoylanilide hydroxamic acid (SAHA)
radiosensitized pediatric sarcoma and rhabdoid tumor
cell-lines in vitro through increase of apoptosis and regu-
lation of the cell cycle as well as down-regulation of
DNA-repair proteins [8]. Knipstein et al. reported that
histone deacetylase inhibitors decrease proliferation and
potentiate the effect of ionizing radiation in two further
rhabdoid tumor cell lines [9].
Our data as well as the data of other groups showed
that the radiosensitization through HDACi is associated
with increased expression of gH2AX in treated tumor
cell lines, supporting the theory that changes in XRT-
induced DNA damage repair plays a role in the radio-
sensitization of tumor cells by HDACi [10]. g-H2Ax
expression was therefore investigated in the treatment
xenograft specimen along with proliferation, apoptosis
and necrosis as further possible underlying mechanisms.
Measurement of glucose metabolism with positron
emission tomography (PET) has become an important
imaging modality in the non-invasive evaluation and
monitoring of malignant diseases. In sarcoma patients,
18F-Fluorodeoxyglucose Positron Emission Tomography
(
18F-FDG PET) has been shown to be useful in staging,
therapy monitoring, and detection of relapse [11]. The
use of PET/CT using F-FDG in rare tumors like MRT is
unclear. Therefore, we were interested in the correlation
of glucose metabolism with clinical and histopathologi-
cal outcome in our xenograft mouse model and
included
18F-FDG PET studies in the first part of our
mouse experiments.
Materials and methods
Cells and reagents
The A-204 human MRT cell line (which is falsely
claimed to be a rhabdomyosarcoma cell line) was
obtained from the American Type Culture Collection
(ATCC; Rockville, MD) and maintained in a complete
culture medium (McCoy) supplemented with 10% FCS.
SAHA was obtained from Alexis Biochemicals (Lörrach,
Germany), DMSO from Carl Roth Biochemicals (Karls-
ruhe, Germany). Ketamine (0.4 mg/20 g BW) and xyla-
zine (Bayer Germany) (90 mg/20 g BW) were used to
anesthetize mice during radiation treatments.
Animal model
Xenografts of human MRT cells were established by
subcutaneous inoculation of 5 × 10
6 A-204 cells into
the hind legs of 10 weeks old female BALB/cNu/Nu
athymic mice (Charles River, Wilmington, Mass.). The
mice were maintained under specific pathogen-free con-
ditions, food and water were supplied ad libitum. Hous-
ing and all procedures involving the mice were
performed according to the protocols approved by the
local regional board.
Two trial cohorts were treated with slight differences
in the treatment regimen.
In our first cohort mice were randomly assigned to
the different treatment groups, when tumors reached
300 mm
3 as PET-imaging prior to therapy was only pos-
sible in rather big tumors. In our second xenograft
cohort we set aside PET-imaging and assigned the
tumors to the different treatment arms when they
reached 100 mm
3.
Cohort I consisted of 12 mice per treatment group,
Cohort II of 10 mice per treatment group.
The four treatment arms were as follows:
1) Vehicle (DMSO) control,
2) SAHA alone (100 mg/kg for 8 days (first cohort of
mice) or 21 days (second cohort of mice)
3) XRT alone (with 1 × 10 Gy in the first cohort and
3 × 3 Gy on 3 consecutive days in the second cohort)
and Combination treatment of SAHA with XRT (corre-
spondingly, Cohort 1:
4 )S A H Af o r8d a y s+1×1 0G yX R T ,C o h o r tI I :
S A H Af o r1 5d a y s( 5d a y s / w e e kf o r3w e e k s )+3×3
Gy XRT).
Initially each group of the first cohort consisted of 13
mice. 1 mouse in the XRT group and 2 mice in the
group with combination treatment died during anesthe-
sia-related complications before XRT. In the second
cohort each treatment group consisted of 10 mice.
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days, when PET-imaging or XRT were performed (day
-1, 0 and day 8).
SAHA 100 mg/kg was solubilized in DMSO (99.5%),
given intraperitoneally (i.p.), starting 24 h before XRT.
The decision to start the SAHA treatment 24 h before
XRT was based on our in vitro data that showed the
highest sensitization of tumor cells after incubation for
24 hours [8]. On day 1, mice tumors were irradiated
w i t has i n g l ed o s eo f1 0G y( C o h o r tI )a n d3×3 G y
(Cohort II), respectively, directed at the tumor site. This
dose corresponds to a tumor growth delay of 20 days
which was determined in a preceding test. During the
follow-up mice were weighed, and the tumor sizes were
measured using a calliper twice a week. Tumor length
(L) and width (W) were measured and tumor volume
calculated as (L × W
2/2), where L = longest diameter
and W = shortest diameter.
A n i m a l sw e r ee u t h a n i z e db yC O 2 inhalation followed
by cervical dislocation when tumors reached 3.5 cm
3 or
latest 65 days after treatment start.
F-18 Fluorodeoxyglucose Positron Emission Tomography
(
18F-FDG-PET)
Dynamic
18F-FDG-PET measurements were performed
in 5 mice per treatment group prior to treatment (day
0 for the untreated control group and XRT group, day
-1 for the SAHA or SAHA plus XRT treated group)
and at the end of treatment (day 8). The PET studies
were performed in list mode for 60 min after intrave-
neous (i.v.) administration of 6 MBq
18F-FDG (in-
house production, German Cancer Research Centre
Heidelberg, Germany) using a matrix of 256 × 256
(pixel size 0.3882 × 0.3882 × 0.796 mm). There after
images were reconstructed at definite time periods
a f t e rt r a c e ra d m i n i s t r a t i o n( 2×1 5s ,8×3 0s ,5×6 0
s, 4 × 120 s, 2 × 210 s, 7 × 300 s). The images were
reconstructed iteratively using the space alternating
generalized expectation maximization method (SAGE,
16 subsets, 4 iterations) applying median root prior
correction. Time-activity curves were created using
volumes of interest (VOIs) over the hearts (input func-
tion) and the tumors. For the input function and the
tissue response curve we used the maximal value of
the VOI data. The following parameters were retrieved
from the dynamic PET studies: standardized uptake
value (SUV) at 50-60 minutes after tracer administra-
tion and the kinetic parameters k1, k2, k3, k4 and VB
o b t a i n e df o r map h a r m a c o k i n e t i ca n a l y s i sa n dt h eF D G
influx calculated using the formula: influx = (k1*k3)/
(k2 + k3). A dedicated micro PET system (Inveon, Sie-
mens, Erlangen, Germany) was used for the animal
studies. The evaluation of the PET-data was performed
using the software package PMOD.
Immunohistochemical analysis
Histomorphological analysis was done in three tumor
samples of each treatment group of Cohort I on day 8
(corresponding to the last day of SAHA treatment) and
at the last day of observation (day 60 at the latest). In
Cohort II histological samples were taken on day 21
(corresponding to the last day of SAHA application in
this Cohort). Tumors excised from euthanized mice
were formalin-fixed and paraffin-embedded. 1 μMt h i c k
sections were cut and stained with hematoxylin-eosin
(HE; Sigma-Aldrich, St Louis, USA). Subsequently, 3
μM thick sections were cut for immunohistochemistry.
Staining for Ki-67 and Myo-D1 was performed as fol-
lows: First, tissue slides were deparaffinated with xylol
and ethanol. To improve antigen retrival slides were
cooked in 0.1 M citrate. Primary antibodies (monoclonal
mouse anti-MyoD1 clone 5.8 A (1:50, over night, 4°C;
Dako, Hamburg, Germany), monoclonal mouse anti-
human Ki-67 clone MIB-1 (1:200, overnight 4°C; Dako,
Hamburg, Germany)) were added. Then, a biotinylated
anti-mouse secondary antibody was administered for 25
min. Endogenous peroxidase was blocked with H2O2 for
7 min. Slides were incubated with a streptavidin HRP
construct (25 min,, Biolegend, San Diego, USA). Subse-
quently, slides were stained with 3-Amino-9-ethylcarba-
z o l e( A E C ;S i g m a - A l d r i c h ,S tL o u i s ,U S A )a n d
counterstained with hemalaun (AppliChem, Darmstadt,
Germany).
Apoptosis was quantified by the in situ apoptosis
detection kit, ApopTAG
® (S7100; Chemicon Interna-
tional (Millipore), Temecula, CA, USA) according to the
manufacturer’s instructions.
All tissue evaluation was done by two trained patholo-
gists (WW and AS).
H&E stainings were evaluated with respect to tumor
cell pleomorphism, number of mitotic cells and extent
of necrosis, estimated visually by an experienced pathol-
ogist. Ki-67 and Myo-D1 staining were quantified by
Spectrum™ software (Aperio, Vista CA, USA).
TUNEL-positive cells were counted in ten high power
fields of each case and a mean was calculated.
Flow cytometry
gH2AX expression was assessed in three xenografts per
treatment group using flow cytometry. Tumor cells were
separated in a solution of 2.1% citrate acid and 0.5%
tween. Tumor cells of three mice per group were
washed with PBS several times and then fixed with 3%
paraformaldehyde (PFA, Sigma) for 10 min at 37°C. Ice-
cold methanol (90%) was added and samples were kept
on ice for another 30 min. Afterwards, samples were
washed three times in 0.5% PBS/BSA, resuspended in
100 μl 0.5% PBS/BSA and incubated for 10 min at RT.
To stain the cells for gH2AX, the antibody (anti-
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Millipore (Molsheim, Germany) was diluted 1:10 in 0.5%
PBS/BSA and 100 μl solution was applied per sample.
After 1 h incubation time at RT, cells were washed
another three times in PBS/BSA. Cells were further
stained with DAPI for 30 min on ice. The samples were
analyzed directly on a “BD™LSRII “- flow cytometer
from “Becton, Dickinson and Company (Franklin Lakes,
New Jersey US)”. The relative fluorescence intensity in
the gated areas was detected using the multiparameter
“BD FACSDiva™” from “Becton, Dickinson and Com-
pany (Franklin Lakes, New Jersey US)” and analysed
with the software “FlowJo7.6.5” by “Tree Star Inc”.T o
assess the mean extent of DNA damage at a particular
phase of the cell cycle, the mean values of gH2AX
immunofluorescence (IF) were calculated separately for
G0/1,Sa n dG 2M cells by the computer-interactive “gat-
ing” analysis. Cells in S and G2M have a 1.5 respectively
2.0 higher gH2AX mean IF compared to cells in G0/1
because of the increase of DNA and histone content
during the cell cycle. Therefore, the data has to be nor-
malized for DNA (histone) content by dividing the
mean gH2AX IF of S- and G2M-phase cells by 1.5 and
2.0, respectively. Finally, a low level of gH2AX IF is seen
in the untreated cells which represent an “intrinsic”
gH2AX phosphorylation. Therefore, the gH2AX IF level
of the untreated controls has to be subtracted from the
IF level of the treated cells in order to get the gH2AX IF
level which is treatment-related.
Data analysis
Actual tumor growth delay was calculated with (T’x-Tx)/
Tx as the time taken for the irradiatied tumors (T’)a n d
the control tumors (T) to x-fold multiply their volume
(x).
The two-sided t-test was used to analyze the differ-
ences between the treatment groups. All data are pre-
sented as the mean +/- standard deviation. P values <
0.05 were considered statistically significant. Local Con-
trol (LC) was defined as the time from the initiation of
treatment until the time a tumor had reached ≥ 1000
mm
3 in size. LC was estimated by Kaplan-Meier curves,
and the differences in TTF between groups were
assessed using log-rank test.
Results
It was previously shown that SAHA is able to enhance
radiosensitivity in MRT cells in vitro [8,9]. To extend
these findings, we now investigated the in vivo radiosen-
sitizing potential of SAHA in a MRT xenograft mouse
model.
During the first 5 days of SAHA treatment, the ani-
mals suffered from loss of appetite. Even though the
mice recovered soon application of SAHA was therefore
not continued consecutively, but discontinued during
weekends in the second cohort and well tolerated. Mice
were weighed twice a week, body weight remained toler-
able (maximum weight loss was 8% and similar in all
treatment groups.
Treatment with XRT respectively XRT plus SAHA
delayed the tumor growth rate compared to treatment
with SAHA alone or untreated controls. After a follow-
up of > 40 days our data showed a trend towards slower
tumor progression in the combined treatment group
compared to xenotransplants treated with XRT alone,
but this was not statistically significant in Cohort I trea-
ted with single-dose XRT and SAHA for 8 days (p =
0.3) (Figure 1a). However, we were able to prove statisti-
cal significance in the second cohort, treated with 3 ×
3Gy fractionated XRT and SAHA for 3 weeks (p < 0.05)
(Figure 2) We calculated local control (absences of local
failure defined as tumor growth > 1000 mm
3) according
to the method of Kaplan and Meier in both cohorts. In
Cohort I 50 days after start of treatment 20% of mice in
the combination group compared to 0% of mice in the
XRT had not experienced local failure (Figure 3). In
cohort II, in which treatment started when tumors were
much smaller, the same trend was intensified with a
local control rate of 85% versus 25% after 60 days in
favor of the combined treatment group. SAHA as a sin-
gle-agent had no influence on local control in our
Figure 1 Tumor progression of malignant rhabdoid tumor
xenografts (MRT) in Cohort I after treatment with ionizing
radiation (XRT) or SAHA and XRT. The y-axis plots the
multiplication of initial tumor size normalized to the initial size = 1,
x-axis plots the time after treatment initiation in days. Figure 1
represents Cohort I and Figure 2 Cohort II. SAHA 100 mg/kg was
injected intraperitoneally once daily for 8 consecutive days in
Cohort I and for 15 days within 3 weeks in Cohort II starting with
day 0. XRT with a single dose of 10 Gy (Cohort I) or with 3 × 3 Gy
on three consecutive days (Cohort II) was delivered day 1(-3). After
a follow-up of > 40 days, there was a trend towards slower
progression in the combined treatment group compared to
xenotransplants treated with XRT alone in Cohort I (p = 0.3), and a
significant difference in Cohort II.(p < 0.05).
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(Cohort I) nor for 3 weeks (Cohort II) (Figure 4).
Actual tumor growth delay was calculated with (T’x-
Tx)/Tx as the time taken for the irradiatied tumors (T’)
and the control tumors (T) to x-fold multiply their
volume (x). Tumor growth delay was significant in
Cohort II (p < 0.05), in which the parameters initial
tumor size, fractionation of radio-treatment and period
of SAHA application had been changed, but not in our
initial Cohort I (Figure 5).
At the last day of treatment (day 8 and day 21 respec-
tively), necrosis was observed in 25% of control tumors
in Cohort I and 8% of tumors in Cohort II. This differ-
ence was attributed to the difference in initial tumor
size at the time treatment was started. Interestingly in
both cohorts any treatment had no statistically signifi-
cant impact on the induction of necrosis. (Table 1, Fig-
ure 6). The analysis of Ki-67 expression on day 8 as well
as day 21 showed significantly higher proliferation rates
(p <0 . 0 3 ,p < 0.02) in the control tumors and the
groups treated with SAHA alone compared to the
groups treated with XRT ± SAHA. However, no statisti-
cally significant difference between the XRT and XRT +
SAHA group was observed in either cohort (Table 1,
Figure 6).
Further, we investigated apoptosis on day 8 (cohort I)
and day 21 (cohort II) in three tumors per treatment
group by TUNEL test. Our results showed a significant
increase of TUNEL positive cells in the tumors with
combination treatment compared to tumors treated
with XRT only (p = 0.03(cohort I) and p < 0.0016
(cohort II)) (Table 1).
We further evaluated induction of DSBs in the differ-
ent treatment groups. It was previously demonstrated
that DSB result in phosphorylation of H2AX on the g-
site of serine 139 to form gH2AX [12-14]. We quantified
the gH2AX expression in the xenograft tumors of three
Figure 2 Tumor progression of malignant rhabdoid tumor
xenografts (MRT) in Cohort II after treatment with ionizing
radiation (XRT) or SAHA and XRT. The y-axis plots the
multiplication of initial tumor size normalized to the initial size = 1,
x-axis plots the time after treatment initiation in days. Figure 1
represents Cohort I and Figure 2 Cohort II. SAHA 100 mg/kg was
injected intraperitoneally once daily for 8 consecutive days in
Cohort I and for 15 days within 3 weeks in Cohort II starting with
day 0. XRT with a single dose of 10 Gy (Cohort I) or with 3 × 3 Gy
on three consecutive days (Cohort II) was delivered day 1(-3). After
a follow-up of > 40 days, there was a trend towards slower
progression in the combined treatment group compared to
xenotransplants treated with XRT alone in Cohort I (p = 0.3), and a
significant difference in Cohort II.(p < 0.05).
Figure 3 Presents In vivo tumor growth of rhabdomyosarcoma
(RMS) xenografts after treatment with 10 Gy single dose
radiation (XRT) or XRT and SAHA for 8 days (Cohort I). Local
failure was defined as a tumor growth > 1000 mm
3. Local Control
was calculated according to the method of Kaplan and Meier. Fifty
days after treatment start.
Figure 4 Presents In vivo tumor growth of rhabdomyosarcoma
(RMS) xenografts after treatment with 3 × 3Gy fractionated
radiation or XRT and SAHA for 3 weeks (Cohort II). Local failure
was defined as a tumor growth > 1000 mm
3. Local Control was
calculated according to the method of Kaplan and Meier. Fifty days
after treatment start.
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with either vehicle control, SAHA 100 mg/kg for two
consecutive days, XRT (10 Gy) or SAHA (100 mg/kg)
on two consecutive days with XRT (10 Gy) on the sec-
ond day of SAHA treatment. The mice were euthanized
30 min, 6 h, 24 h and 36 h after treatment, tumors were
excised and analyzed for gH2AX expression using flow
cytometry. After 30 min, a single XRT dosage of 10 Gy
resulted in a 3.4 (± 1)-fold induction of gH2AX expres-
sion compared to the vehicle control. Tumors of mice
treated with XRT and SAHA showed a significantly
higher induction (p = 0.03) of gH2AX expression (8 ±
Figure 5 Actual tumor growth delay was calculated with (T’x-Tx)/Tx as the time taken for the irradiatied tumors (T’) and the control
tumors (T) to x-fold multiply their volume (x). The y-Axis shows tumor growth delay in days, the x-axis shows the tumor growth (T’x-Tx)/Tx.
Tumor growth delay was significant in Cohort II (p < 0.05), but not in our initial Cohort I.
Table 1 Ki67-expression/Necrosis (%) and Apoptosis (TUNEL test) in RMS xenografts treated with vehicle (DMSO),
suberoylanilide hydroxamic acid (SAHA), irradiation (XRT), or SAHA and XRT in the first and second mouse cohort
observed day 8 (cohort I) and day 21 (Cohort II)
Treatment Mean Tumor Age (days) Mean (SD) Ki-67 (%) HE (necrosis)(%) TUNEL (apoptosis)
Cohort I Cohort II Cohort I CohortII Cohort I CohortII Cohort I CohortII
Control 39 (± 3) 37 42 (± 16) 45 (± 12) 25 (± 11) 8 (± 6) 64 (± 9) 55 (± 9)
SAHA 36 (± 1) 37 53 (± 10) 32 (± 11) 23 (± 9) 10 (± 6) 118 (± 15) 97 (± 12)
XRT 36 (± 1) 37 21 (± 4) 24 (± 7) 42 (± 12) 10 (± 5) 148 (± 24) 126 (± 12)
SAHA + XRT 36 (± 1) 37 14 (± 8) 17 (± 4) 48 (± 17) 12 (± 6) 201 (± 11) 192 (± 10)
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as a single agent resulted in no increase of gH2AX
expression compared to the vehicle control (Figure 7).
Investigation of further time points revealed that gH2AX
expression decreased successively from 2 h to 6 h and
24 h after XRT. Interestingly 24 h after XRT, gH2AX
expression of irradiated tumors reached the level of the
untreated controls whereas the tumors of the combina-
tion group still showed an elevated expression level (2-
fold ± 0.5).
Dynamic PET was used for tumor imaging to evaluate
therapy response as previously described in animals
after transfer of antiangiogenic genes [15]. In a preced-
ing test four PET-tracers were tested in 6 mice with our
sarcoma xenograft with every tracer being tested in 3
mice: FDG (
18F-fluordeoxyglucose), FLT (
18F-3’-deoxy-
3’-L-thymidine),
68 Ga-RGD (aνb3/aνb5 integrin-bind-
ing peptide) and FET (
18F-fluoro-ethyl-tyrosine).
18F-
FDG-PET showed the best results. Therefore, dynamic
18F-FDG-PET was performed in 5 mice per treatment
group before and on day 8 after treatment with SAHA,
XRT or XRT plus SAHA (Table 2).
Comparing the results prior to and after treatment in
each group there was no statistically significant effect on
the standard uptake value (SUV) or on the transport of
glucose into the tumor (k1) or out of the tumor (k2) in
the different treatment groups. There was also no statis-
tically significant impact on the hexokinase activity (k3)
by any treatment modality examined. The vascular frac-
tion (VB) increased in the control group, but equally
decreased in all treated tumor groups. Therefore, FDG-
PET did not seem to be an interesting option to moni-
tor MRT treatment response in our mouse trial and was
therefore discontinued after treatment of Cohort I.
Discussion
This is the first in vivo study that shows, that vorinostat
has the potential to sensitize MRT to radiation.
Patients with malignant rhabdoid tumors still have a
poor prognosis despite intensive current treatment pro-
tocols. Radiotherapy plays a significant role in local
treatment, but is often delayed as long as possible in
young children as late sequelae are feared. Therfore
there is a need for new treatment strategies.
Figure 6 H&E, TUNEL and Ki67 staining of tumor tissue from MRT xenografts treated with vehicle, suberoylanilide hydroxamic acid
(SAHA), ionizing radiation (XRT) or SAHA and XRT. See also Table 1.
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shown promising results in different tumor types. SAHA
is one of the well-established HDACi which has been
approved in the United States by the Food and Drug
Administration (FDA) for the therapy for human cuta-
neous T-cell lymphoma. The drug can be given orally
and side-effects are minor compared to cytotoxic che-
motherapeutics. Therefore, it is an interesting candidate
for tumor therapy. The promise of HDACi for cancer
treatment, as a single agent and in combination with
standard therapies, is supported by in vitro results of
colorectal carcinoma, human melanoma and glioma cell
experiments [4,5,7]. In several trials combination of
HDACi with chemotherapy or radiotherapy improved
tumor cell kill [4,7,16,17]. However, in vivo studies with
HDACi as single-agent in cancer treatment, showed
only moderate and limited efficacy [18].
Based on our promising in vitro results that showed a
selectively radiosensitizing effect in the A-204 cell line
used in this experiment as well as in two osteosarcoma
cell lines, we now investigated the efficacy of the
HDACi SAHA in combination with radiotherapy, com-
pared to SAHA or XRT only in a MRT xenograft
mouse model.
The results of our first Cohort did show a trend
towards an improved local control and tumor growth
delay in mice treated with SAHA plus XRT compared
to animals treated with XRT alone. We attributed the
lack of significance in Cohort I to three possible para-
meters: 1. short period of SAHA application, 2. fractio-
nation of radiation and 3. rather big tumor size at time
of treatment initiation.
SAHA has previously been shown to augment the
effects of radiotherapy in vivo tumor models [3,6,16]. In
some of these in vivo studies, the drug was applied for
several weeks with successful radiosensitization [7,19],
even though in others short-term application for 5 days
and even single-dose treatment prior to irradiation
seemed to be sufficient [7,19].
The underlying pathways of HDACi acting as a radio-
sensitizer are still not completely understood [20]. Abro-
gation of DSB repair has been suggested to be one
possible mechanism by several authors [10,16]. In our
experiments, gH2AX expression, representing DNA-
damage, was significantly influenced by the combination
treatment. Interestingly, gH2AX expression of irradiated
tumors reached the level of the untreated controls 24 h
after XRT, whereas the tumors of the combination
Figure 7 gH2AX expression in MRT xenografts treated with
ionizing radiation (XRT) or suberoylanilide hydroxamic acid
(SAHA) and XRT. The mice were treated with either vehicle control,
SAHA 100 mg/kg for two consecutive days, XRT (10 Gy) or SAHA
(100 mg/kg) on two consecutive days with XRT (10 Gy) on the
second day of SAHA treatment. After 30 min, tumors of mice
treated with XRT and SAHA showed a significantly higher induction
of gH2AX expression compared to tumors treated with XRT alone.
gH2AX expression decreased successively from 2 h to 6 h and 24 h
after XRT. 24 h after XRT, gH2AX expression of irradiated tumors
reached the level of the untreated controls whereas the tumors of
the combination group showed still an elevated expression level.
Table 2 Descriptive statistics of the mean value and its standard deviation as well as the median values prior and
after treatment of rhabdoid tumor xenografts with vehicle (DMSO), suberoylanilide hydroxamic acid (SAHA),
irradiation (XRT) or XRT and SAHA
Parameter Control SAHA XRT SAHA + XRT
Mean (SD)
prior
Mean (SD)
after
Mean (SD)
prior
Mean (SD)
after
Mean (SD)
prior
Mean (SD)
after
Mean (SD)
prior
Mean (SD)
after
k1 0.015 (0.04) 0.13 (0.06) 0.16 (0.04) 0.1 (0.01) 0.14 (0.01) 0.16 (0.02) 0.14 (0.01) 0.15 (0.05)
k2 0.32 (0.07) 0.38 (0.02) 0.37 (0.12) 0.24 (0.08) 0.33 (0.03) 0.34 (0.02) 0.39 (0.03) 0.39 (0.02)
k3 0.08 (0.03) 0.11 (0.06) 0.07 (0.04) 0.1 (0.08) 0.06 (0.02) 0.08 (0.02) 0.08 (0.01) 0.09 (0.00)
VB 0.01 (0.001) 0.02 (0.002) 0.03 (0.002) 0.01 (0.001) 0.04 (0.001) 0.01 (0.001) 0.04 (0.003) 0.01 (0.001)
Influx constant Ki (=
(k1xk3)/(k2+k3)
0.03 0.03 0.02 0.03 0.02 0.03 0.02 0.03
Max mSUV 1323 (368) 1593 (631) 2341 (1135) 729 (305) 1676 (782) 1578 (1206) 1314 (767) 1158 (816)
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Page 8 of 10group showed still an elevated expression level (2-fold ±
0.5), thus showing an impairment of repair kinetics by
the combination treatment. Therefore, we assumed
improved results after fractionated XRT and decided to
treat Cohort II with 3 × 3Gy instead of 1 × 10 Gy.
We wanted to use our first Cohort to investigate the
potential of PET-imaging in our malignant rhabdoid
tumor model. As the results were disappointing, we
refrained from PET-imaging and thus were able to start
treatment in smaller tumors in Cohort II.
These changes did indeed lead to a higher clinical
impact resulting in significancy in Cohort II. As we
decided to change all three parameters we can only
guess which change has the highest impact and it
remains unclear, if fractionation is obligatory or not. In
previous reports on xenograft studies concerning breast
tumors, neuroblastoma and ovarian cancer combination
of HDACIs with fractionated [7,17] as well as single-
dose irradiation [19] have been reported to be
successful.
Interestingly - in contrast to reports concerning in
vivo models of other tumor types [16,17,20]- application
of SAHA as a single agent had no effect in both of our
experimental designs in this MRT xenotransplant model
- neither when given for 8 days, nor for 3 weeks. Our
SAHA dose, especially in Cohort II with 100 mg/kg for
5 consecutive days for 3 weeks is rather high compared
to other studies [7,17,19,20], in which SAHA proved to
be successful. In these studies application differed from
once 50 mg/kg, 3 × 150 mg within 1 week, 5 × 12,5
mg/week for 3 weeks and indeed 24 × 50 mg within 8
weeks. We therefore conclude from our study, that
SAHA only treatment in MRT is not too promising.
We observed a strong trend towards a lower prolifera-
tion activity in the combination groups compared to the
XRT alone groups. However, this trend failed to reach
statistical significance in both cohorts.
Looking at necrosis of tumors, results showed no sig-
nificant differences between the control group, SAHA
group and the XRT or XRT plus SAHA group. How-
ever, apoptosis was indeed significantly higher in the
XRT (p =0 , 0 0 1 )a sw e l la sX R T+S A H Ag r o u p s( p =
0,0001) compared to the controls in both cohorts and
also significantly higher in both XRT + SAHA groups
compared to SAHA only (p > 0,0016). Thus, induction
of apoptosis rather than necrosis seems to have the
higher impact on radiosensitization by SAHA. However,
as far as apoptosis was concerned the effect of SAHA +
XRT seemed to be rather additive, while tumor growth
delay in the mice seemed to be a rather synergistic
effect given that SAHA alone had no significant effect at
all. This proves again that apoptosis remains to be just
one of the -all in all not completely understood - under-
lying mechanisms of radiosensitization.
We attribute the fact that no changes in our dynamic
18F-FDG-PET/CT images were to be observed to this
lack of all investigated treatment schedules to induce
significant necrosis in MRT. However, a further reason
may be the initial tumor size (mean tumor size 300
mm3), which we chose in Cohort I in order to at all
allow PET imaging [21], but which also may have attrib-
uted to the lower impact of the overall treatment that
was observed in Cohort I compared to Cohort II.
Conclusions
SAHA is a promising radiosensitizer in malignant rhab-
doid tumors, while it has no significant effect as a
mono-agent. The addition of SAHA to radiotherapy
does favorably and significantly influence apoptosis and
DNA-repair kinetics in MRT xenotransplants, whereas
necrosis is not influenced.
Acknowledgements
The skillfull technical assistance of Ludmilla Frick, Sylvia Trinh, Gabriele
Becker, Alexandra Tietz, Angela Funk, Andreas Griesbach and Karin Leotta is
gratefully acknowledged. The project was supported by the “Deutsche
Krebshilfe” and the Dietmar Hopp Stiftung, Germany.
Author details
1Department of Radiation Oncology, University of Heidelberg, INF 600, 69120
Heidelberg, Germany.
2Institute of Pathology, University of Heidelberg, 69120
Heidelberg, Germany.
3Department of Radiation Oncology, German Cancer
Research Center, 69120 Heidelberg, Germany.
4Department of Nuclear
Medicine, University of Heidelberg and DKFZ, 69120 Heidelberg, Germany.
5Department of Pediatric Oncology, Hematology and Immunology,
University Children’s Hospital of Heidelberg, 69120 Heidelberg, Germany.
Authors’ contributions
MT designed methods, carried out the experiments and analysed the data.
SO co-designed the research theme, interpreted the results and wrote
paper. VE helped to design of the flow-cytometry experiments and to
interpret the results. WW and AS carried out the histopathological
assessment in the tumor specimen and helped to interpret the results. MB
and K-JW helped by discussing analyses, interpretation and presentation. RLP
carried out and analyzed flow-cytometry assessment of y-H2AX experiments.
UH designed and helped to analyze PET-experiments. AK co-designed the
research theme. JD co-designed the research theme and provided the
laboratory and radiation facilities. PEH co-analysed and co-discussed the
data. CB designed the research theme, analysed and co-discussed all results.
All authors contributed to and approved this manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 August 2011 Accepted: 29 March 2012
Published: 29 March 2012
References
1. Buscariollo DL, Park HS, Roberts KB, et al: Survival outcomes in atypical
teratoid rhabdoid tumor for patients undergoing radiotherapy in a
Surveillance Epidemiology, and End Results analysis. Cancer 2011.
2. Morgenstern DA, Gibson S, Brown T, et al: Clinical and pathological
features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer
2010, 51(1):29-34.
3. Graham JS, Kaye SB, Brown R: The promises and pitfalls of epigenetic
therapies in solid tumors. Eur J Cancer 2009, 45:1129-1136.
4. Folkvord S, Ree AH, Furre T, et al: Radiosensitization by SAHA in
experimental colorectal carcinoma models - in viv effects and relevance
Thiemann et al. Radiation Oncology 2012, 7:52
http://www.ro-journal.com/content/7/1/52
Page 9 of 10of histone acetylation status. Int J Radiat Oncol Biol Phys 2009,
74(2):546-552.
5. Munshi A, Kurland JF, Nishikawa T, et al: Histone deacetylase inhibitors
radiosensitize human melanoma by suppressing DNA repair activity. Clin
Cancer Res 2005, 11:4912-4922.
6. Chinnaiyan P, Vallabhaneni G, Armstrong E, et al: Modulation of radiation
response by histone deacetylase inhibition. Int J Radiation Oncology Biol
Phy 2005, 62:223-229.
7. Entin-Meer M, Yang X, Vandenburg SR, et al: In viv efficacy of a novel
histone deacetylase inhibitor in combination with radiation for the
treatment of gliomas. Neuro Oncol 2007, 9:82-88.
8. Blattmann C, Oertel S, Ehemann V, et al: Enhancement of radiation
response in osteosarcoma and rhabdomyosarcoma cell lines by histone
deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010, 78:237-245.
9. Knipstein JA, Birks DK, Donson AM, et al: Histone deacetylase inhibition
decreases proliferation and potentiates the effect of ionizing radiation in
atypical teratoid/rhabdoid tumor cells. Neuro Oncol 2012.
10. Munshi A, Tanaka T, Hobbs ML, et al: Vorinostat, a histone deacetylase
inhibitor, enhances the response of human tumor cells to ionizing
radiation through prolongation of gamma-H2AX foci. Molecular Cancer
Therapy 2006, 5:1967-1974.
11. Denecke T, Hundsdörfer P, Misch D, et al: Assessment of histological
response of paediatric bone sarcomas using FDG PET in comparison to
morphological volume measurement and standardized MRI parameters.
Eur J Nucl Med Mol Imaging 2010, 37:1842-1853.
12. Paull TT, Rogakou EP, Yamazaki V, et al: A critical role for histone H2AX in
recruitment of repair factors to nuclear foci after DNA damage. Curr Biol
2000, 10:886-895.
13. Huang X, Darzynkiewicz Z: Cytometric assessment of histone H2AX
phosphorylation: Method. Mol Biol 2006, 314:73-80.
14. Olive PL, Banath JP: Phosphorylation of histone H2AX as a measure of
radiosensitivity. Int J Radiation Oncology Biol Phys 2003, 58:331-335.
15. Haberkorn U, Hoffend J, Schmidt K, et al: Changes in glucose metabolism
and gene expression after transfer of anti-angiogenic genes in rat
hepatoma. Eur J Nucl Med Mol Imaging 2007, 34(12):2011-2023.
16. Lopez G, Liu J, Ren W, et al: Combining PCI-24781, a novel histone
deacetylase inhibitor, with chemotherapy for the treatment of soft
tissue sarcoma. Clin Cancer Res 2009, 15(19):3472-3483.
17. Mueller S, Yang X, Sottero TL, et al: Cooperation of the HDAC inhibitor
vorinostat and radiation in metastatic neuroblastoma: efficacy and
underlying mechanisms. Cancer Lett 2011, 306(2):223-229.
18. Siu LL, Pili R, Duran I, et al: Phase I study of MGCD0103 given as a three-
times-per-week oral dose in patients with advanced solid tumors. J Clin
Oncol 2008, 26:1940-1947.
19. Baschnagel A, Russo A, Burgan WE, et al: Vorinostat enhances the
radiosensitivity of a breast cancer brain metastatic cell line grown in
vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8(6):1589-1595.
20. Chen MY, Liao WS, Lu Z, et al: Decitabine and suberoylanilide hydroxamic
acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts
while inducing expression of imprinted tumor suppressor genes,
apoptosis, G2/M arrest, and autophagy. Cancer 2011, 16 DOI: 10.1002/
cncr.26073.
21. Arvanitis C, Bendapudi PK, Tseng JR, et al: (18)F and (18)FDG PET imaging
of osteosarcoma to non-invasively monitor in situ changes in cellular
proliferation and bone differentiation upon MYC inactivation. Cancer Biol
Ther 2008, 7(12):1947-1951.
doi:10.1186/1748-717X-7-52
Cite this article as: Thiemann et al.: In vivo efficacy of the histone
deacetylase inhibitor suberoylanilide hydroxamic acid in combination
with radiotherapy in a malignant rhabdoid tumor mouse model.
Radiation Oncology 2012 7:52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thiemann et al. Radiation Oncology 2012, 7:52
http://www.ro-journal.com/content/7/1/52
Page 10 of 10